1. Introduction {#sec1-marinedrugs-17-00006}
===============

Marine natural products (NPs) are an important source for developing new drugs, especially those from marine-derived fungi which possess novel structures and significant biological activities \[[@B1-marinedrugs-17-00006],[@B2-marinedrugs-17-00006]\]. *Aspergillus* is a kind of productive fungal genus and has been reported to produce many new NPs \[[@B3-marinedrugs-17-00006]\], such as alkaloids \[[@B4-marinedrugs-17-00006],[@B5-marinedrugs-17-00006],[@B6-marinedrugs-17-00006]\], diketopiperazines \[[@B7-marinedrugs-17-00006],[@B8-marinedrugs-17-00006]\], xanthones \[[@B8-marinedrugs-17-00006]\], and diphenyl ethers \[[@B9-marinedrugs-17-00006]\]. However, the whole genome sequencing studies of fungi have indicated that most genes of fungi were silent and not expressed in the conventional experimental conditions. Fungi treated with DNA methyltransferase and histone deacetylase inhibitors enhanced NPs' chemical diversity, demonstrating that small molecule epigenetic modifiers are effective tools for rationally generating new and bioactive NPs \[[@B10-marinedrugs-17-00006]\]. Both molecular-based and chemical approaches targeting histone and DNA posttranslational processes have the great potential for rationally activating or suppressing NP-encoding gene clusters \[[@B11-marinedrugs-17-00006],[@B12-marinedrugs-17-00006],[@B13-marinedrugs-17-00006]\]. Epigenetic modification has become a widely applied strategy to find new and bioactive NPs today \[[@B14-marinedrugs-17-00006],[@B15-marinedrugs-17-00006],[@B16-marinedrugs-17-00006]\].

In our continuous study on the discovery of new and bioactive NPs from algicolous microorganisms isolated from *Enteromorpha prolifera* by epigenetic modification \[[@B12-marinedrugs-17-00006],[@B13-marinedrugs-17-00006]\] and other strategies \[[@B17-marinedrugs-17-00006],[@B18-marinedrugs-17-00006],[@B19-marinedrugs-17-00006]\], we found that the algicolous *Aspergillus versicolor* OUCMDZ-2738 could produce different NPs after chemical-epigenetic modification by 10 µM SAHA. From the epigenetically modified fermentation of *A. versicolor* OUCMDZ-2738, we isolated and identified a new naturally occurring compound **1**, two new enantiomers ((+)-**2** and (‒)-**2**), and thirteen known compounds (**3**--**12**). Their structures were determined as 3-\[6-(2-methylpropyl)-2-oxo-1*H*-pyrazin-3-yl\] propanamide (**1**), (+)-brevianamide X ((+)-**2**) and (‒)-brevianamide X ((‒)-**2**), (±)-brevianamide R (**3**) \[[@B20-marinedrugs-17-00006]\], (±)-brevianamide Q (**4**) \[[@B20-marinedrugs-17-00006]\], brevianamide V ((+)-**5**) \[[@B21-marinedrugs-17-00006]\], brevianamide W ((‒)-**5**) \[[@B22-marinedrugs-17-00006]\], brevianamide K (**6**) \[[@B23-marinedrugs-17-00006]\], diorcinol B (**7**) \[[@B24-marinedrugs-17-00006]\], diorcinol C (**8**) \[[@B24-marinedrugs-17-00006]\], diorcinol E (**9**) \[[@B24-marinedrugs-17-00006]\], diorcinol J (**10**) \[[@B24-marinedrugs-17-00006]\], diorcinol (**11**) \[[@B25-marinedrugs-17-00006]\], and methyl diorcinol-4-carboxylate (**12**) \[[@B26-marinedrugs-17-00006],[@B27-marinedrugs-17-00006]\], respectively ([Figure 1](#marinedrugs-17-00006-f001){ref-type="fig"}). (±)-Brevianamide R (**3**) and (±)-brevianamide Q (**4**) were further resolved as (+)- and (‒)- brevianamide R ((+)- and (‒)- **3**) and (+)- and (‒)- brevianamide Q ((+)- and (‒)- **4**), respectively.

2. Results and Discussion {#sec2-marinedrugs-17-00006}
=========================

Compound **1** was isolated as a brown, amorphous powder. The molecular formula was determined as C~11~H~17~O~2~N~3~ by a HRESIMS peak at *m*/*z* 246.1205 \[M + Na\]^+^ (calcd for C~11~H~17~O~2~N~3~Na, 246.1213) ([Supplementary Figure S1](#app1-marinedrugs-17-00006){ref-type="app"}). 1D ([Table 1](#marinedrugs-17-00006-t001){ref-type="table"} and [Supplementary Figures S2 and S3](#app1-marinedrugs-17-00006){ref-type="app"}) and HSQC ([Supplementary Figure S5](#app1-marinedrugs-17-00006){ref-type="app"}) NMR spectra displayed one sp^2^ methine (δ~C~ 120.8, δ~H~ 7.01), one sp^3^ methine (δ~C~ 27.5, δ~H~ 1.91), three sp^3^ methylenes (δ~C~ 27.6, δ~H~ 2.79; δ~C~ 31.1, δ~H~ 2.41; δ~C~ 38.4, δ~H~ 2.25), and two methyls (δ~C~ 21.9, δ~H~ 0.86; δ~C~ 21.9, δ~H~ 0.84) ([Table 1](#marinedrugs-17-00006-t001){ref-type="table"}). The HMBC ([Supplementary Figure S7](#app1-marinedrugs-17-00006){ref-type="app"} and [Figure 2](#marinedrugs-17-00006-f002){ref-type="fig"}) correlations from H-7 (δ~H~ 2.79), H-8 (δ~H~ 4.64), and NH~2~ (δ~H~ 7.30, δ~H~ 6.72) to carbonyl carbon (δ~C-9~ 173.7) along with the ^1^H--^1^H COSY ([Supplementary Figure S6](#app1-marinedrugs-17-00006){ref-type="app"} and [Figure 2](#marinedrugs-17-00006-f002){ref-type="fig"}) between H-7 and H-8 indicated a 3-substituted propionamide moiety. ^1^H--^1^H COSY correlations from H-10 (δ~H~ 2.25) to H-12 (δ~H~ 0.86), and H-13 (δ~H~ 0.84) through H-11 (δ~H~ 1.91), demonstrated an isobutyl fragment. The remaining fragment, C~4~H~2~ON~2~, could be a pyrazin-2(1*H*)-one nucleus from the HMBC correlations from H-4 (δ~H~ 7.01) to C-3 (δ~C~ 155.2) and C-6 (δ~C~ 138.0). Furthermore, the key HMBC correlations from H-10 to C-5 (δ~C~ 120.8) and C-6, and H-7 to C-2 (δ~C~ 156.2) and C-3, allowed for the linkage of the isobutyl to C-6 and the 3-substituted propionamide moiety to C-3, respectively. Thus, structure **1** was established as 3-\[6-(2-methylpropyl)-2-oxo-1*H*-pyrazin-3-yl\] propenamide, which was only recorded in the Aurora Fine Chemicals with ID number K13.052.726 without any physical and chemical properties reported. Consequently, **1** was identified as a new naturally occurring compound.

The racemic **2** was isolated as light yellow crystal with the molecular formula of C~21~H~23~N~3~O~4~ from a HRESIMS peak at *m*/*z* 404.1570 \[M + Na\]^+^ (calcd for C~21~H~23~N~3~O~4~Na, 404.1581) ([Supplementary Figure S8](#app1-marinedrugs-17-00006){ref-type="app"}). Its 1D ([Table 1](#marinedrugs-17-00006-t001){ref-type="table"} and [Supplementary Figures S9 and S10](#app1-marinedrugs-17-00006){ref-type="app"}) and HSQC ([Supplementary Figure S12](#app1-marinedrugs-17-00006){ref-type="app"}) NMR spectra displayed two methyls (δ~C~ 28.1, δ~H~ 1.57; δ~C~ 28.3, δ~H~ 1.54), two sp^3^ methylenes (δ~C~ 44.7, δ~H~ 3.96, δ~H~ 3.72; δ~C~ 29.0, δ~H~ 1.93, δ~H~ 2.41), one sp^3^ methine (δ~C~ 76.4, δ~H~ 4.41), five sp^2^ methines (δ~C~ 115.1, δ~H~ 7.29; δ~C~ 120.2, δ~H~ 7.37; δ~C~ 121.3, δ~H~ 7.07; δ~C~ 122.6, δ~H~ 7.12; δ~C~ 122.6, δ~H~ 7.43), and one sp^2^ methylene (δ~C~ 112.6, δ~H~ 5.10, 5.13), which demonstrated the presence of a monosubstituted double bond ([Table 1](#marinedrugs-17-00006-t001){ref-type="table"}). ^1^H--^1^H COSY ([Supplementary Figure S13](#app1-marinedrugs-17-00006){ref-type="app"} and [Figure 2](#marinedrugs-17-00006-f002){ref-type="fig"}) from H-21 (δ~H~ 6.11) to H-22 (δ~H~ 5.10; δ~H~ 5.13) and the HMBC ([Supplementary Figure S14](#app1-marinedrugs-17-00006){ref-type="app"} and [Figure 2](#marinedrugs-17-00006-f002){ref-type="fig"}) from H-21 (δ~H~ 6.11) to C-20 (δ~C~ 40.5), C-23 (δ~C~ 28.1), and C-24 (δ~C~ 28.3), along with H-23 (δ~H~ 1.57) to C-20 and C-24, which demonstrated the presence of a 2-methylbut-3-en-2-yl fragment. The ^1^H--^1^H COSY correlations from H-13 (δ~H~ 7.37) to H-16 (δ~H~ 7.43), along with the HMBC from H-13 (δ~H~ 7.37) to C-12 (δ~C~ 127.4), C-11 (δ~C~ 104.5), and C-17 (δ~C~ 127.4), and H-16 (δ~H~ 7.43) to C-12 and C-17, which demonstrated the presence of a 2,3-bisubstituted indole ring. Moreover, the key HMBC from H-21, H-23, and H-24 (δ~H~ 1.54) to C-19 (δ~C~ 146.2) connected the 2-methylbut-3-en-2-yl group to C-19 of the indole ring. Chemical shifts of C-1 (δ~C~ 165.7) and C-4 (δ~C~ 161.3) indicated two amide carbonyl carbons. In addition, ^1^H--^1^H COSY correlations from H-6 (δ~H~ 3.72; δ~H~ 3.96) to H-8 (δ~H~ 4.41) through H-7 (δ~H~ 1.93; δ~H~ 2.41) and HMBC correlations from H-6 to C-4 and C-9 (δ~C~ 91.0), H-7 to C-9, H-8 (δ~H~ 4.41) to C-1 and C-9 and, H-10 (δ~H~ 7.29) to C-3 (δ~C~ 125.1) and C-4 were observed. This data indicated a 2-methylene-(2,3-dihydroxytetrahydro) pyrrolo\[1,2-*a*\] diketopiperazine nucleus. The key HMBC correlations from H-10 to C-11, C-12, and C-19 ([Figure 2](#marinedrugs-17-00006-f002){ref-type="fig"}) allowed for the linkage of the isopentenylindole and tetrahydropyrrolo\[1,2-*a*\] diketopiperazine moieties by a C-11--C-10 sigma bond. Thus, the planar structure of **2** was determined as 9-hydroxybrevianamide Q. A literature survey showed that **2** has the same planar structure as brevianamide U without resolution of the configuration (${\lbrack\mathsf{\alpha}\rbrack}_{D}^{21}$ +20 (*c* 0.17, MeOH)) \[[@B21-marinedrugs-17-00006]\]. Although their ^1^H and ^13^C NMR data were similar, they displayed obvious different chemical shifts of C-1 and C-9 in ^13^C NMR, indicating the different configurations. The configuration of **2** was confirmed by X-ray single crystallographic diffraction that clearly indicated *trans*-configuration between 8-OH and 9-OH and the *Z*-geometry of the ∆^3(10)^-double bond ([Figure 3](#marinedrugs-17-00006-f003){ref-type="fig"}). However, the X-ray crystallographic results were space group P-1 and the planus line of the electronic circular dichroism (ECD) spectrum indicated **2** might be a pair of enantiomers. Thus, two enantiomers with 1.1:1 ratio of HPLC peaks area were separated by a chiral column ([Supplementary Figure S15A](#app1-marinedrugs-17-00006){ref-type="app"}), whose specific rotations were ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ +44 and --40 (*c* 0.05, MeOH), respectively. The absolute configurations of (+)-**2** and (--)-**2** were respectively assigned as (8*S*, 9*S*) and (8*R*, 9*R*) by comparing the experimental and calculated ECD values obtained using TD-DFT at the B3LYP/6-31G(d) level \[[@B19-marinedrugs-17-00006],[@B28-marinedrugs-17-00006],[@B29-marinedrugs-17-00006]\] ([Figure 4](#marinedrugs-17-00006-f004){ref-type="fig"}). Therefore, we named (+)-**2** and (--)-**2** as (+)-brevianamide X and (--)-brevianamide X, respectively.

The planar structures of compounds **3**--**5** were reported previously without assignment of the absolute configurations \[[@B20-marinedrugs-17-00006],[@B22-marinedrugs-17-00006]\]. Their small specific rotations, ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ +10 (*c* 0.82, MeOH) for **3**, ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ --7 (*c* 1.75, MeOH) for **4**, and ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ +19 (*c* 0.33, MeOH) for **5**, indicated that compounds **3**--**5** might be enantiomeric mixtures, perhaps having an excess of one of the enantiomers. They were analyzed and resolved by chiral HPLC. As we expected, (±)-**3**, (±)-**4**, and (±)-**5** were further separated into their optically pure enantiomers ([Supplementary Figure S15B--D](#app1-marinedrugs-17-00006){ref-type="app"}). The absolute configurations were determined by comparing the experimental ECD with those calculated using TD-DFT at the B3LYP/6-31G(d) level ([Figure 4](#marinedrugs-17-00006-f004){ref-type="fig"}). As a result, compounds (+)-**3** and **4** were assigned to have a 9*R*-configuration, while the (--)-**3** and **4** were assigned a 9*S*-configuration. This is the first time that racemic brevianamides R (**3**), Q (**4**), and V (**5**) have been resolved into their chiral enantiomers and their absolute configurations have been determined.

The structures of **6**--**11** were determined by comparing their NMR data and specific rotations those reported \[[@B23-marinedrugs-17-00006],[@B24-marinedrugs-17-00006],[@B25-marinedrugs-17-00006]\]. Although the structure of **12** has been previously reported in the references, there were no ^13^C NMR data \[[@B26-marinedrugs-17-00006]\] and nor NMR solvent reported \[[@B27-marinedrugs-17-00006]\], and chemical shifts of **12** ([Table 2](#marinedrugs-17-00006-t002){ref-type="table"}) were obviously different to those in ref. \[[@B27-marinedrugs-17-00006]\]. The difficulty was in the assignment of the position of the methoxycarbonyl group at C-2′ or C-4′. Thus, its dimethyl ether (**12a**) was prepared from **12** by reaction with MeI/K~2~CO~3~ and the 2D NMR of both **12** ([Supplementary Figures S21--S23](#app1-marinedrugs-17-00006){ref-type="app"}) and **12a** ([Supplementary Figures S27--S29](#app1-marinedrugs-17-00006){ref-type="app"}) were recorded. The ROESY correlations of CH~3~O-5′ (δ~H~ 3.72) with H-6′(δ~H~ 6.61) and the protons (δ~H~ 3.78) of the methyl ester in **12a** ([Supplementary Figure S28](#app1-marinedrugs-17-00006){ref-type="app"} and [Figure 5](#marinedrugs-17-00006-f005){ref-type="fig"}) located the methoxycarbonyl group at C-4′. Therefore, the structures of compounds **12** and **12a** were determined as methyl diorcinol-4-carboxylate and methyl 3,3′-di(*O*-methyl) diorcinol-4-carboxylate, respectively.

A plausible biosynthetic relationship linking **2**--**6** through a sequence of oxidative transformations and hydrolysis or methanolysis is illustrated in [Figure 6](#marinedrugs-17-00006-f006){ref-type="fig"}. Positions 8 and 9 in **6** have no steric hindrance when performing electrophilic addition or oxidation. Therefore, it is easy to form enantiomeric mixtures or excess of **2**--**5**.

HPLC-UV was used to identify which compounds are solely produced under SAHA. Both extracts, generated with and without addition of SAHA, were analyzed using the same elution gradient. Compared to those in the same medium without SAHA, epigenetic modification with SAHA enhanced the NP diversity of *A. versicolor* OUCMDZ-2738 and the compounds **1**--**4**, **8**, **9**, **11**, and **12** were solely observed under SAHA condition. This demonstrated SAHA as the actual inducer to produce compounds **1**--**4**, **8**, **9**, **11**, and **12** ([Supplementary Figure S31](#app1-marinedrugs-17-00006){ref-type="app"} and [Figure 7](#marinedrugs-17-00006-f007){ref-type="fig"}), further indicating that chemically epigenetic regulation is an effective method for expanding the chemical space of fungal natural products.

All the isolated compounds (**1**--**12**) were evaluated for antibacterial activity against a panel of pathogenic microorganisms, including four Gram-positive bacteria, (*Bacillus subtilis* ATCC6051, *Clostridium perfringens* ATCC13048, *Staphylococcus aureus* ATCC6538, and *Staphylococcus aureus* ATCC25923), two Gram-negative bacteria (*Pseudomonas aeruginosa* ATCC10145 and *Escherichia coli* ATCC11775), and two pathogenic fungi (*Candida albicans* ATCC10231, *Candida glabrata* ATCC2001). The results showed that compound **11** selectively inhibited *P. aeruginosa* while **12** inhibited *P. aeruginosa* and *C. glabrata* with MIC values of 17.4, 13.9, and 27.8 μM, respectively ([Table 3](#marinedrugs-17-00006-t003){ref-type="table"}). The inhibitory activities of **1**--**12** against *α*-glucosidase from *Saccharomyces cerevisiae* were also evaluated using the pNPG method. Only compounds **9**--**11** displayed *α*-glucosidase inhibitory activity with IC~50~ values of 117.3, 237.4 and 275.3 μM, respectively. Acarbose, used as the assay control, had an IC~50~ of 255.3 μM.

3. Materials and Methods {#sec3-marinedrugs-17-00006}
========================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-17-00006}
------------------------------------

Optical rotations were measured using an AUTOPOL1 polarimeter (Rudolph Research Analytical, Hackettstown, NJ, USA). UV spectra were measured on a Beckman DU 640 spectrophotometer (Beckman Coulter, Inc., Brea, CA, USA). ECD spectra were measured on JASCOJ-715 spectropolarimeter (JASCO Corporation, Tokyo, Japan). IR spectra were taken on a Nicolet Nexus 470 spectrophotometer (Thermo Nicolet Corporation, Madison, WI, USA) as KBr disks. 1D (one-dimensional) and 2D (two-dimensional) NMR spectra were recorded on an INOVA-400MHz spectrometer with TMS (tetramethylsilane) as the internal standard. ESIMS and HRESIMS were carried out on a Waters 2695 LCQ-MS liquid chromatography mass spectrometer (Thermo Finnigan, San Francisco, CA, USA). Semi-preparative HPLC separations were performed using a Hitachi Primaide Organizer HPLC system (Hitachi High-Tech Science Corporation, Tokyo, Japan). YMC-Pack ODS-A column (S-5 μm, 12 nm, 250 × 4.6 mm and S-5 μm, 12 nm, 250 × 10 mm, Shenzhen Chemist Technology Co. Ltd., Shenzhen, China). Chiral column (Lux^®^ 5 µm Cellulose-2 and Lux^®^ 5 µm i-Cellulose-5, LC Column 250 × 4.6 mm., Phenomenex, CA, USA). Thin layer chromatography (TLC) and column chromatography (CC) were performed on plates precoated with silica gel GF 254 (10--40 µm) and over silica gel (200--300 mesh, Qingdao Marine Chemical Factory, Qingdao, China), respectively. Chemical reagents for isolation were analytical grade (Tianjin Kaixin Chemical Industry Co., Ltd., Tianjin, China); chromatographic grade MeOH for HPLC was from Tianjin Siyou Fine Chemicals Co., Ltd., Tianjin, China.

3.2. Fungal Material {#sec3dot2-marinedrugs-17-00006}
--------------------

The fungus *Aspergillus versicolor* OUCMDZ-2738 was isolated from a piece of fresh tissue from the *Enteromorpha prolifera*, collected from the Shilaoren beach, Qingdao, China, in July 2012 \[[@B12-marinedrugs-17-00006],[@B13-marinedrugs-17-00006]\]. The pure cultures were deposited in the Key Laboratory of Marine Drugs, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong province, China, with the GenBank (NCBI) accession number MH150818.

3.3. Cultivation and Extraction of Strain OUCMDZ-2738 {#sec3dot3-marinedrugs-17-00006}
-----------------------------------------------------

The cultivation and extraction process were the same described in previous papers \[[@B12-marinedrugs-17-00006],[@B13-marinedrugs-17-00006]\], and the EtOAc solutions were concentrated under reduced pressure to give a crude extract (13.1 g).

3.4. Purification {#sec3dot4-marinedrugs-17-00006}
-----------------

The crude extract was applied to a silica gel (200--300 mesh) column and was separated into twelve fractions (Fr.1 to Fr.12) using a step-gradient elution of petroleum ether/EtOAc (0--100%) and CHCl~3~/MeOH.

Fr.1 (0.2 g) was purified by semipreparative HPLC (50:50 MeOH/H~2~O, 4 mL/min) to give **1** (11.6 mg, *t*~R~ 9.6 min). Fr.12 (0.24 g) was purified by semipreparative HPLC (70:30 MeOH/H~2~O, 4 mL/min) to give the racemic-**2** (8.0 mg, *t*~R~ 6.5 min). Fr.7 (0.85 g) was separated on a preparative TLC eluted with CH~2~Cl~2~/CH~3~OH (*v/v*, 30:1), then subfraction Fr.7-1 (142.0 mg) was purified by semipreparative HPLC (70:30 MeOH/H~2~O, 4 mL/min) to give compound **6** (78.6 mg, *t*~R~ 6.4 min). Subfraction Fr.7-3 (101 mg) was purified by semipreparative HPLC (50:50 MeOH/H~2~O, 4 mL/min) to give racemic-**4** (9.3 mg, *t*~R~ 8.3 min). Subfraction Fr.7-4 (75 mg) was purified by semipreparative HPLC (60:40 MeOH/H~2~O, 4 mL/min) to give **9** (10.5 mg, *t*~R~ 7.0 min) and **8** (5.3 mg, *t*~R~ 8.1 min). Fr.8 (0.42 g) was separated on a preparative TLC eluted with CH~2~Cl~2~/MeOH (*v*/*v*, 50:1), then subfraction Fr.8-1 (178.3 mg) was purified by semipreparative HPLC (65:35 MeOH/H~2~O, 4 mL/min) to give racemic-**3** (7.3 mg, *t*~R~ 8.0 min) and racemic-**5** (90.0 mg, *t*~R~ 8.5 min). Fr.5 (0.21 g) was purified by semipreparative HPLC (70:30 MeOH/H~2~O, 4 mL/min) to give **7** (40.8 mg, *t*~R~ 9.7 min) and **10** (9.8 mg, *t*~R~ 8.7 min). Fr.4 (0.12 g) was purified by semipreparative HPLC (65:35 MeOH/H~2~O, 4 mL/min) to give **11** (14.6 mg, *t*~R~ 6.7 min). Fr.2 (0.18 g) was purified by semipreparative HPLC (70:30 MeOH/H~2~O, 4 mL/min) to give **12** (48.6 mg, *t*~R~ 7.3 min). The racemic-**2** was resolved as the optically pure (+)-**2** (1.0 mg, *t*~R~ 13.7 min) and (--)-**2** (1.1 mg, *t*~R~ 10.5 min) by semi-preparative HPLC (25:75 MeCN/H~2~O, 0.9 mL/min) equipped with a chiral column (Lux^®^ 5 µm Cellulose-2, LC Column 250 × 4.6 mm, Phenomenex). Using the same procedure, the racemic **3** and **4** were chirally separated as the optically pure (-)-**3** (1.3 mg, *t*~R~ 6.5 min), (+)-**3** (1.5 mg, *t*~R~ 5.7 min), (+)-**4** (2.1 mg, *t*~R~ 4.3 min) and (--)-**4** (2.2 mg, *t*~R~ 4.8 min) by a chiral HPLC column (80:20 MeOH/H~2~O, 0.9 mL/min) (+)-**5** (35.6 mg, *t*~R~ 7.1 min) and (-)-**5** (20.9 mg, *t*~R~ 9.8 min) were chirally separated by semi-preparative HPLC (80:20 MeOH/H~2~O, 0.9 mL/min) equipped with a chiral column (Lux^®^ 5 µm i-Cellulose-5, LC Column 250 × 4.6 mm, Phenomenex).

3-\[6-(2-Methylpropyl)-2-oxo-1*H*-pyrazin-3-yl\]propanamide (**1**): a brown amorphous powder, mp 141--143 °C; UV (MeOH) λ~max~ (log *ε*) 217 (3.75), 230 (3.79), 262 (3.15), 325 (3.66) nm; IR (KBr) ν~max~ 3400, 3198, 2959, 2929, 2861, 1655, 1614, 1529, 1408, 1168, 575 cm^−1^; ^1^H and ^13^C NMR data ([Table 1](#marinedrugs-17-00006-t001){ref-type="table"}); HRESIMS *m*/*z* 246.1205 \[M + Na\]^+^ (calculated for C~11~H~17~O~2~N~3~Na, 246.1213).

(±)-Brevianamide X (**2**): light yellow crystal; UV (MeOH) λ~max~ (log *ε*) 233 (4.34), 245 (4.33), 287 (4.18), 329 (4.19), 357 (4.20) nm; IR (KBr) ν~max~ 3351, 2968, 1684, 1620, 1427, 1326, 1244, 1107, 1062, 1022, 979, 960, 921, 749, 655, 584, 518 cm^−1^; ^1^H and ^13^C NMR data ([Table 1](#marinedrugs-17-00006-t001){ref-type="table"}); ESI-MS *m*/*z* 404 \[M + Na\]^+^; HRESIMS *m*/*z* 404.1570 \[M + Na\]^+^ (calculated for C~11~H~17~O~2~N~3~Na, 404.1581). (+)-**2**: mp 241--243 °C; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ + 44 (*c* 0.05, MeOH); ECD (0.0014 M, MeOH) *λ*~max~ (Δ*ε*) 208.5 (--6.5), 261 (+3.9), 337 (--2.5) nm. (--)-**2**: mp 220--222 °C; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$--40 (*c* 0.05, MeOH); ECD (0.001 M, MeOH) *λ*~max~ (Δ*ε*) 208.5 (+6.4), 261 (--3.8), 337 (+2.4) nm.

(±)-Brevianamide R (**3**): a colorless powder; ESI-MS *m*/*z* 402.2 \[M + Na\]^+^; ^1^H and ^13^C NMR (see [supporting information](#app1-marinedrugs-17-00006){ref-type="app"}). (+)-**3**: mp 121--123 °C; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ +208 (*c* 0.15, MeOH); ECD (0.007 M, MeOH) *λ*~max~ (Δ*ε*) 212 (+26.2), 258 (--19.1), 342 (+11.8) nm. (--)-**3**: mp 140--142 °C; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ --213 (*c* 0.13, MeOH); ECD (0.007 M, MeOH) *λ*~max~ (Δ*ε*) 212 (--25.9), 258 (+16.7), 340.5 (--10.8) nm.

(±)-Brevianamide Q (**4**): a colorless powder; ESI-MS *m*/*z* 388.2 \[M + Na\]^+^; ^1^H and ^13^C NMR (see [supporting information](#app1-marinedrugs-17-00006){ref-type="app"}). (+)-**4**: mp 141--143 °C; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ +105 (*c* 0.2, MeOH); ECD (0.003 M, MeOH) *λ*~max~ (Δ*ε*) 212 (+21.8), 258 (--14.3), 340 (+9.3) nm. (--)-**4**: mp 160--163 °C; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ --109 (*c* 0.2, MeOH); ECD (0.003 M, MeOH) *λ*~max~ (Δ*ε*) 213 (--19.3), 258 (+15.8), 340 (--9.7) nm.

(±)-Brevianamide V (**5**): a light yellow powder; ESI-MS *m*/*z* 372.3 \[M + Na\]^+^; ^1^H and ^13^C NMR (see [supporting information](#app1-marinedrugs-17-00006){ref-type="app"}). (+)-**5**: mp 128--130 °C; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ +40 (*c* 2.0, MeOH); ECD (0.0014 M, MeOH) *λ*~max~ (Δ*ε*) 212 (+24.3), 258 (--12.2), 330 (+6.3) nm. (--)-**5**: mp 131--132 °C; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{25}$ --38 (*c* 2.0, MeOH); ECD (0.001 M, MeOH) *λ*~max~ (Δ*ε*) 213 (--22.2), 258 (+11.0), 330 (--5.7) nm.

Methyl diorcinol-4-carboxylate (**12**): a white solid; UV (MeOH) λ~max~ (log *ε*) 224 (3.42), 262 (2.95), 200 (1.36), 301 (1.23) nm; IR (KBr) ν~max~ 3401, 2954, 1656, 1598, 1454, 1322, 1262, 1207, 1161, 1104, 1031, 998, 952, 843, 677 cm^−1^; ^1^H and ^13^C NMR (see [Table 2](#marinedrugs-17-00006-t002){ref-type="table"}); ESI-MS *m*/*z* 311.1 \[M +Na\]^+^.

Methyl 3,3-di(*O*-methyl) diorcinol-4-carboxylate (**12a**): a white solid; UV (MeOH) λ~max~ (log *ε*) 222 (3.34), 228 (3.32), 279 (1.49) nm; IR (KBr) ν~max~ 3440, 2950, 1731, 1587, 1463, 1324, 1268, 1193, 1158, 1093, 1064, 1028, 996, 935, 836 cm^−1^; ^1^H and ^13^C NMR (see [Table 2](#marinedrugs-17-00006-t002){ref-type="table"}); HRESIMS *m*/*z* 317.1392 \[M + H\]^+^ (calculated for C~18~H~21~O~5~, 317.1384) ([Supplementary Figure S24](#app1-marinedrugs-17-00006){ref-type="app"}).

3.5. Crystallographic Data for Racemic ***2*** {#sec3dot5-marinedrugs-17-00006}
----------------------------------------------

Racemic **2** was obtained as a light-yellow monoclinic crystal with molecular formula C~11~H~17~O~2~N~3~ from CH~3~CH~2~OH and CH~2~Cl~2~. Space group P-1, *a* = 9.8007 (9) Å, *b* = 10.4560(12) Å, *c* = 12.9125(14) Å, *α* = 122.466(3)°, *β* = 97.4200(10)°, *γ* = 106.988(2)°, V = 1125.2(2) Å3, *Z* = 2, *D*~calcd~ = 1.259 mg/m^3^, *μ* = 0.089 mm^-1^, *F*(000) = 454, crystal size 0.34 × 0.21 × 0.13 mm, T = 298(2) K, 2.27° ≤ 2θ ≤ 25.02°, 5737 reflections collected, 3915 unique (R(int) = 0.0364). Final R indices R^1^ = 0.0310, wR^2^ = 0.0748 based on 3915 reflections with *I* \> 2 *sigma*(*I*) (refinement on F^2^), 316 parameters, 0 restraint. Crystallographic data (excluding structure factors) for structure (±)-**2** in this dissertation have been deposited in the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 1837585 (fax, +44-(0)-1223-336033; e-mail, <deposit@ccdc.cam.ac.uk>).

3.6. ECD Calculation Assays {#sec3dot6-marinedrugs-17-00006}
---------------------------

The calculations were performed by using the density functional theory (DFT) using Gaussian 03. The preliminary conformational distributions search was performed by HyperChem 7.5 software. All ground-state geometries were optimized at the B3LYP/6-31G(d) level. Conformers within a 2 kcal/mol energy threshold from the global minimum were selected to calculate the electronic transitions. The overall theoretical ECD spectra were obtained according to the Boltzmann weighting of each conformers. Solvent effects of methanol solution were evaluated at the same DFT level by using the SCRF/PCM method.

3.7. Methylation of ***12*** {#sec3dot7-marinedrugs-17-00006}
----------------------------

To a solution of 12 (10 mg) in DMF (1 mL) were added K~2~CO~3~ (20 mg) and MeI (0.03 mL), and the mixture was then stirred for 2 h \[[@B30-marinedrugs-17-00006]\]. The reaction was stopped by the addition of water (10 mL) and extracted three times with EtOAc (3 × 20 mL), then EtOAc solutions were concentrated under reduced pressure. The mixture was purified by semi-HPLC (80:20 MeOH/H~2~O, 4 mL/min) to give dimethylether derivative 12a (7.4 mg, *t*~R~ 7.8 min).

3.8. Antimicrobial Assays {#sec3dot8-marinedrugs-17-00006}
-------------------------

The MICs of the compounds were tested using the broth microdilution method \[[@B31-marinedrugs-17-00006],[@B32-marinedrugs-17-00006]\]. The pathogenic bacteria included *B. subtilis* ATCC6051, *S. aureus* ATCC6538, *S. aureus* ATCC25923, *P. aeruginosa* ATCC10145, *E. aerogenes*, and *E. coli* ATCC11775 and the pathogenic fungi were *C. albicans* ATCC10231, and *C. glabrata* ATCC2001. Ciprofloxacin and ketoconazole were used as positive controls against bacteria and fungi, respectively. All of the microbial strains used in the bioassays are preserved at the Key Laboratory of Chemistry for Natural Products of Guizhou Province, Chinese Academy of Sciences.

3.9. α-Glucosidase Inhibitory Effect Assays {#sec3dot9-marinedrugs-17-00006}
-------------------------------------------

The inhibitory effects were assayed as described previously \[[@B12-marinedrugs-17-00006],[@B13-marinedrugs-17-00006],[@B33-marinedrugs-17-00006]\]. Absorbance of 96-well plates at 405 nm was recorded by an Epoch microplate reader (BioTek Instruments, Inc., Winooski, VT, USA). Acarbose was used as a positive control with an IC~50~ value of 255.3 μM.

4. Conclusions {#sec4-marinedrugs-17-00006}
==============

We identified sixteen compounds from the fermentation of *Aspergillus versicolor* OUCMDZ-2738 under chemical-epigenetic modification, including a new naturally occurring diketopiperazine derivative (**1**) and two new compounds, (+)-brevianamide X ((+)-**2**) and (--)-brevianamide X ((--)-**2**). We also chirally separated the racemic brevianamides R (**3**), Q (**4**), and V (**5**) into the corresponding optically pure compounds and resolved their absolute configurations for the first time. We clearly determined the structure of the methyl diorcinol-4-carboxylate (**12**) by preparing 3,3′-dimethylether derivative (**12a**). Compounds **11** and **12** showed selective antibacterial activity against *P. aeruginosa* both with the MIC value of 17.4 and 13.9 μM, respectively.

The following are available online at <http://www.mdpi.com/1660-3397/17/1/6/s1>, Figure S1. HRESIMS spectrum of compound **1**; Figure S2--S7. NMR spectrum of compound **1**; Figure S8. HRESIMS spectrum of compound **2**; Figure S9--S14. NMR spectrum of compound **2**; Figure S15. The chiral HPLC analysis of compounds **2**--**5**; Figure S16. The chiral HPLC analysis of compounds **7**--**9**; Figure S17. DFT-optimized structures for low-energy conformers of compounds **2**--**5**; Figure S18. Phylogenetic tree mapping for the *Aspergillus versicolor* OUCMDZ-2738; Figure S19--S23. NMR spectrum of compound **12**; Figure S24. HRESIMS spectrum of compound **12a**; Figure S25--S29. NMR spectrum of compound **12a**; Figure S30. The UPLC-MS Analysis of Fermented Extracts. Figure S31. Retention times of compounds **1**--**12** in the same elution gradient with original extract fingerprint. The physical properties of the known compounds **3**--**11**.

###### 

Click here for additional data file.
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###### 

^1^H (400 MHz) and ^13^C (100 MHz) NMR data of **1** in DMSO-*d*~6~ and **2** in MeOH-*d*~4~.

  No.     1             2                                 
  ------- ------------- ------------------ -------------- --------------------------------
  1                     12.01, brs         165.7, C       
  2       156.2, C                                        
  3       155.2, C                         125.1, C       
  4                                        161.3, C       
  5       120.8, CH     7.01, s                           
  6       138.0, C                         44.7, CH~2~    3.96, m; 3.72, m
  7       27.6, CH~2~   2.79, t (7.5)      29.0, CH~2~    1.93, m; 2.41, m
  8       31.1, CH~2~   2.41, t (7.5)      76.4, CH       4.41, m
  9       173.7, C                         91.0, C        
  10      38.4, CH~2~   2.25, d (7.3)      115.1, CH      7.29, s
  11      27.5, CH      1.91, m            104.5, C       
  12      21.9, CH~3~   0.85, d (6.6)      127.4, C       
  13      21.9, CH~3~   0.85, d (6.6)      120.2, CH      7.37, d (7.9)
  14                                       121.3, CH      7.07, dd (7.9, 7.9)
  15                                       122.6, CH      7.12, dd (7.9, 7.9)
  16                                       112.6, CH      7.43, d (7.9)
  17                                       136.8, C       
  NH~2~                 6.72, s; 7.30, s                  
  19                                       146.2, C       
  20                                       40.5, C        
  21                                       146.1, CH      6.11, dd (17.3, 10.6)
  22                                       112.6, CH~2~   5.10, d (10.6); 5.13, d (17.3)
  23                                       28.1, CH~3~    1.57, s
  24                                       28.3, CH~3~    1.54, s
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###### 

^1^H (400 MHz) and ^13^C (100 MHz) NMR data of **12** and **12a** in DMSO-*d*~6~.

  No.       12            12a                   12 \[[@B27-marinedrugs-17-00006]\]                                 
  --------- ------------- --------------------- ------------------------------------ --------------- ------------- ---------------
  1         156.4, C                            156.9, C                                             155.9, C      
  2         103.8, CH     6.22, dd (1.2, 1.2)   102.3, CH                            6.42, d (1.2)   105.0, CH     6.44, brs
  3         158.6, C                            160.5, C                                             156.8, C      
  4         112.1, CH     6.41, brs             110.4, CH                            6.58, brs       112.6, CH     6.49, brs
  5         140.5, C                            140.6, C                                             141.2, C      
  6         110.8, CH     6.30, brs             111.7, CH                            6.42, d (1.2)   113.4, CH     6.37, brs
  1′        159.1, C                            158.4, C                                             162.3, C      
  2′        110.9, CH     6.35, d (2.1)         111.2, CH                            6.40, d (2.1)   113.0, CH     6.37, d (2.5)
  3′        139.1, C                            137.5, C                                             143.6, C      
  4′        114.8, C                            118.6, C                                             107.0, CH     
  5′        157.7, C                            157.6, C                                             165.0, C      
  6′        102.7, CH     6.27, d (2.1)         100.2, CH                            6.61, d (2.1)   103.2, CH     6.34, d (2.5)
  1′′       168.6, C                            167.6, C                                             172.0, C      
  5-Me      21.1, CH~3~   2.20, s               21.2, CH~3~                          2.25, s         21.4, CH~3~   2.28, s
  3′-Me     20.2, CH~3~   2.21, s               19.0, CH~3~                          2.14, s         24.2, CH~3~   2.50, s
  3-OMe                                         55.3, CH~3~                          3.72, s                       
  5′-OMe                                        56.0, CH~3~                          3.72, s                       
  1′′-OMe   51.9, CH~3~   3.78, s               52.1, CH~3~                          3.78, s         51.9, CH~3~   3.94, s
  3-OH                    10.21, brs                                                                               11.66, s
  5′-OH                   9.61, brs                                                                                
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###### 

Antimicrobial bioassay results of active compounds.

  Compounds       MIC (μM)                                                   
  --------------- ---------- ------- ------- ------- ------- ------- ------- -------
  **1**           \>200      \>200   \>200   \>200   \>200   \>200   \>200   \>200
  **2**           \>200      \>200   \>200   \>200   \>200   \>200   \>200   \>200
  **3**           \>200      \>200   \>200   \>200   \>200   \>200   \>200   \>200
  **4**           \>200      \>200   \>200   \>200   \>200   \>200   \>200   \>200
  **5**           \>200      \>200   \>200   \>200   \>200   \>200   \>200   \>200
  **6**           \>200      92.2    \>200   184.4   \>200   184.4   \>200   \>200
  **7**           \>200      \>200   \>200   \>200   \>200   \>200   \>200   \>200
  **8**           \>200      46.2    \>200   \>200   \>200   184.8   \>200   \>200
  **9**           \>200      101.9   \>200   \>200   \>200   \>200   \>200   \>200
  **10**          \>200      50.9    \>200   \>200   \>200   \>200   \>200   \>200
  **11**          69.6       17.4    139.2   \>200   \>200   \>200   \>200   \>200
  **12**          \>128      13.9    55.6    \>200   \>200   55.6    111.2   27.8
  Ciprofloxacin   48.4       96.8    0.75    0.75    12.1    0.75    ND      ND
  Ketoconazole    ND         ND      ND      ND      ND      ND      7.6     3.8

^a^ ATCC 6538, ^b^ ATCC 25923, ND: not detection.

[^1]: These authors contributed equally to this paper.
